Acute Unilateral Central Serous Chorioretinopathy after Immunization with Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Literature Review

References

• Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. May, 2020;19(5):305–306. doi:10.1038/d41573-020-00151-8.
   PubMed Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. May 21, 2020;382(21):1969–1973. doi:10.1056/NEJMp2005630.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. December 10, 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• COVID C, Team R. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. Morbidity Mortality Weekly Rep. January 15, 2021;70(2):46.
   PubMed Web of Science ®Google Scholar
• Álvarez-Twose I. Delving into COVID-19 vaccination-induced anaphylaxis: are mRNA vaccines safe in mast cell disorders? J Investig Allergol Clin Immunol. February, 2021;31 (2) :193–195 doi:10.18176/jiaci.0680 .
   PubMed Web of Science ®Google Scholar
• Cakir B, Reich M, Lang S, et al. OCT angiography of the choriocapillaris in central serous chorioretinopathy: a quantitative subgroup analysis. Ophthalmol Ther. March, 2019;8(1):75–86. doi:10.1007/s40123-018-0159-1.
   PubMed Web of Science ®Google Scholar
• Teussink MM, Breukink MB, van Grinsven Mj, et al. OCT angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci. August 1, 2015;56(9):5229–5237. doi:10.1167/iovs.15-17140.
   PubMed Web of Science ®Google Scholar
• Rochepeau C, Kodjikian L, Garcia MA, et al. Optical coherence tomography angiography quantitative assessment of choriocapillaris blood flow in central serous chorioretinopathy. Am J Ophthalmol. October 1, 2018;194:26–34. doi:10.1016/j.ajo.2018.07.004.
   PubMed Web of Science ®Google Scholar
• Liew G, Quin G, Gillies M, Fraser‐Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. March, 2013;41(2):201–214. doi:10.1111/j.1442-9071.2012.02848.x.
   PubMed Web of Science ®Google Scholar
• Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. March, 2008;86(2):126–145. doi:10.1111/j.1600-0420.2007.00889.x.
   PubMed Web of Science ®Google Scholar
• Fowler N, Martinez NR, Pallares BV, Maldonado RS. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine. Am J Ophthalmol Case Rep. September 1, 2021;23:101136. doi:10.1016/j.ajoc.2021.101136.
   PubMedGoogle Scholar
• Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. April 1, 2003;110(4):698–703. doi:10.1016/S0161-6420(02)01975-9.
   PubMed Web of Science ®Google Scholar
• Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–126. doi:10.1016/j.survophthal.2012.07.004.
   PubMed Web of Science ®Google Scholar
• Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. July 2, 2012;122(7):2672–2679. doi:10.1172/JCI61427.
   PubMed Web of Science ®Google Scholar
• Fischer S, Gerriets T, Wessels C, et al. Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. Blood J Am Soc Hematol. October 1, 2007;110(7):2457–2465.
   Google Scholar
• Cunha-Vaz J . The blood–retinal barrier in retinal disease. European Ophthalmic Review. October 27, 2009;3:105-108. doi:10.17925/EOR.2009.03.02.105 . .
   Google Scholar
• Jung SH, Kim KA, Sohn SW, Yang SJ. Cytokine levels of the aqueous humour in central serous chorioretinopathy. Clin Exp Optometry. May 1, 2014;97(3):264–269. doi:10.1111/cxo.12125.
   PubMed Web of Science ®Google Scholar
• Iijima H, Iida T, Murayama K, Imai M, Gohdo T. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol. April 1, 1999;127(4):477–478. doi:10.1016/S0002-9394(98)00378-X.
   PubMed Web of Science ®Google Scholar
• Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899. doi:10.2147/OPTH.S12583.
   PubMedGoogle Scholar
• Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc National Acad Sci. April 10, 2007;104(15):6388–6393. doi:10.1073/pnas.0608647104.
   PubMed Web of Science ®Google Scholar
• Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol. June, 2021;8:1.
   Google Scholar
• Bialasiewicz AA, Farah-Diab MS, Mebarki HT. Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine. Int Ophthalmol. August 23, 2021;41(1):1–4. doi:10.1007/s10792-020-01545-8.
   PubMedGoogle Scholar
• Ikegami Y, Numaga J, Okano N, Fukuda S, Yamamoto H, Terada Y. Combined central retinal artery and vein occlusion shortly after mRNA-SARS-CoV-2 vaccination. QJM: Int J Med. December, 2021;114(12):884–885. doi:10.1093/qjmed/hcab287.
   Web of Science ®Google Scholar
• Girbardt C, Busch C, Al-Sheikh M, et al. Retinal vascular events after mRNA and adenoviral-vectored COVID-19 Vaccines—A case series. Vaccines (Basel). November, 2021;9(11):1349. doi:10.3390/vaccines9111349.
   PubMed Web of Science ®Google Scholar
• Karska‐Basta I, Pociej‐Marciak W, Chrząszcz M, Kubicka‐Trząska A, Romanowska‐Dixon B, Sanak M. Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy. Acta Ophthalmol. March, 2021;99(2):e222–31. doi:10.1111/aos.14547.
   PubMed Web of Science ®Google Scholar
• Terao N, Koizumi H, Kojima K, et al. Association of upregulated angiogenic cytokines with choroidal abnormalities in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci. December 3, 2018;59(15):5924–5931. doi:10.1167/iovs.18-25517.
   PubMed Web of Science ®Google Scholar
• Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer. December, 2021;20(1):1–20. doi:10.1186/s12943-021-01339-1.
   PubMed Web of Science ®Google Scholar
• Piccolino FC, Lupidi M, Cagini C, et al. Choroidal vascular reactivity in central serous chorioretinopathy. Invest Ophthalmol Vis Sci. August 1, 2018;59(10):3897–3905. doi:10.1167/iovs.18-23995.
   PubMed Web of Science ®Google Scholar
• Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, Central Serous Chorioretinopathy Case–Control Study Group. Risk factors for central serous chorioretinopathy: a case–control study. Ophthalmology. February 1, 2004;111(2):244–249. doi:10.1016/j.ophtha.2003.09.024.
   PubMed Web of Science ®Google Scholar
• Bouhanick B, Montastruc F, Tessier S, et al. Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal. Eur J Clin Pharmacol. August, 2021;7:1–2.
   Google Scholar
• Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G. CHUV COVID vaccination center. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination. Hypertension. June, 2021;77(6):e56–7. doi:10.1161/HYPERTENSIONAHA.121.17316.
   PubMed Web of Science ®Google Scholar
• Stone JCA, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol: Pract. May 1, 2019;7(5):1533–1540. doi:10.1016/j.jaip.2018.12.003.
   PubMed Web of Science ®Google Scholar
• Wenande E, Garvey LH. Immediate‐type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. July, 2016;46(7):907–922. doi:10.1111/cea.12760.
   PubMed Web of Science ®Google Scholar
• Patel S, Barnett JM, Kim SJ. Retinal toxicity of intravitreal polyethylene glycol 400. J Ocul Pharmacol Ther. March 1, 2016;32(2):97–101. doi:10.1089/jop.2015.0069.
   PubMed Web of Science ®Google Scholar
• Lyzogubov VV, Tytarenko RG, Liu J, Bora NS, Bora PS. Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization. J Biol Chem. May 6, 2011;286(18):16229–16237. doi:10.1074/jbc.M110.204701.
   PubMed Web of Science ®Google Scholar
• Fernandez-Bueno I, Alonso-Alonso ML, Garcia-Gutierrez MT, Diebold Y. Reliability and reproducibility of a rodent model of choroidal neovascularization based on the subretinal injection of polyethylene glycol. Mol Vis. 2019;25:194.
   PubMed Web of Science ®Google Scholar
• Phylactou M, Li JP, Larkin DF. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. British J Ophthalmol. July 1, 2021;105(7):893–896. doi:10.1136/bjophthalmol-2021-319338.
   PubMed Web of Science ®Google Scholar
• Rallis KI, Ting DS, Said DG, Dua HS. Corneal graft rejection following COVID-19 vaccine. Eye 36 . August 23, 2021;1319–1320 doi:10.1038/s41433-021-01671-2.
   PubMed Web of Science ®Google Scholar
• Crnej A, Khoueir Z, Cherfan G, Saad A. Acute corneal endothelial graft rejection following COVID-19 vaccination. J Fr Ophtalmol. October 1, 2021;44(8):e445–e447. doi:10.1016/j.jfo.2021.06.001.
   PubMed Web of Science ®Google Scholar
• Wasser LM, Roditi E, Zadok D, Berkowitz L, Weill Y. Keratoplasty rejection after the BNT162b2 messenger RNA vaccine. Cornea. August, 2021;40(8):1070. doi:10.1097/ICO.0000000000002761.
   PubMed Web of Science ®Google Scholar
• Abousy M, Bohm K, Prescott C, Bonsack JM, Rowhani-Farid A, Eghrari AO. Bilateral EK rejection after COVID-19 vaccine. Eye Contact Lens. November 1, 2021;47(11):625–628. doi:10.1097/ICL.0000000000000840.
   PubMed Web of Science ®Google Scholar
• Balidis M, Mikropoulos D, Gatzioufas Z, de Politis Pb, Sidiropoulos G, Vassiliadis V. Acute corneal graft rejection after anti-severe acute respiratory syndrome-coronavirus-2 vaccination: a report of four cases. Eur J Ophthalmol. November 2021;26:11206721211064033.
   Google Scholar
• Mudie LI, Zick JD, Dacey MS, Palestine AG. Panuveitis following vaccination for COVID-19. Ocul Immunol Inflamm. July 2021;2:1–2.
   Google Scholar
• Renisi G, Lombardi A, Stanzione M, Invernizzi A, Bandera A, Gori A. Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence? Int J Infect Dis. September 1, 2021;110:95–97. doi:10.1016/j.ijid.2021.07.035.
   PubMed Web of Science ®Google Scholar
• Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association.Retina. August 2, 2021; 41(12): 2462–2471. doi:10.1097/IAE.0000000000003277 . , .
   PubMed Web of Science ®Google Scholar
• Maleki A, Look-Why S, Manhapra A, Foster CS. COVID-19 recombinant mrna vaccines and serious ocular inflammatory side effects: real or coincidence? J Ophthalmic Vis Res. July, 2021;16(3):490.
   PubMed Web of Science ®Google Scholar
• Koong LR, Chee WK, Toh ZH, Ng XL, Agrawal R, Ho SL. Vogt-koyanagi-harada disease associated with COVID-19 mRNA vaccine. Ocul Immunol Inflamm. September, 2021;12:1–4.
   Google Scholar
• Valenzuela DA, Groth S, Taubenslag KJ, Gangaputra S. Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination. Am J Ophthalmol Case Rep. December 1, 2021;24:101200. doi:10.1016/j.ajoc.2021.101200.
   PubMedGoogle Scholar
• Chen S, Hodge C. Comment on: ‘Acute macular neuroretinopathy following COVID-19 vaccination’. Eye. 2021. doi:10.1038/s41433-021-01781-x.
   Web of Science ®Google Scholar
• Atas F, Kaya M, Saatci AO. Acute multifocal placoid pigment epitheliopathy-like presentation following the first dose of BNT162B2 COVID-19 vaccination. Ocul Immunol Inflamm. December, 2021;3:1–4. doi:10.1080/09273948.2021.1995763.
   Google Scholar
• Iwai S, Takayama K, Sora D, Takeuchi M. A case of acute retinal necrosis associated with reactivation of varicella zoster virus after COVID-19 vaccination. Ocul Immunol Inflamm. November, 2021;15:1–3. doi:10.1080/09273948.2021.2001541.
   Google Scholar
• Khochtali S, Krifa H, Zina S, et al. Multimodal imaging of acute foveolitis following COVID-19 vaccination. Ocul Immunol Inflamm. October, 2021;25:1–4. doi:10.1080/09273948.2021.1993270.
   Google Scholar
• Subramony R, Lin LC, Knight DK, Aminlari A, Belovarski I. Bilateral retinal detachments in a healthy 22-year-old female following moderna SARS-CoV-2 vaccination. J Emerg Med. July 20, 2021;61(6):e146–e150. doi:10.1016/j.jemermed.2021.07.034.
   PubMed Web of Science ®Google Scholar
• Goyal M, Murthy SI, Annum S. Bilateral multifocal choroiditis following COVID-19 vaccination. Ocul Immunol Inflamm. July, 2021;28:1–5. doi:10.1080/09273948.2021.1900877.
   Google Scholar
• Mambretti M, Huemer J, Torregrossa G, Ullrich M, Findl O, Casalino G. Acute macular neuroretinopathy following coronavirus disease 2019 vaccination. Ocul Immunol Inflamm. July, 2021;1:1–4.
   Google Scholar
• Leber HM, Sant’Ana L, da Silva Nr K, et al. Acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination with coronaVac: a case report. Ocul Immunol Inflamm. August, 2021;16:1–7.
   Google Scholar
• ElSheikh RH, Haseeb A, Eleiwa TK, Elhusseiny AM. Acute uveitis following COVID-19 vaccination. Ocul Immunol Inflamm. August, 2021;8:1–3.
   Google Scholar